`
`a
`
`Division of Ethlc<>l'I, Inc.
`
`March 17, 2009
`
`Novartis Pharma AG
`Fabrikstrasse 12-4.03A.10
`CH-4002 Basel
`Switzerland
`
`Attention:
`
`Ladies and Gentlemen:
`
`This Letter Agreement (the "Agreement") will confirm recent discussions between Advanced
`Sterilization Product division of Ethicon, lnc.("ASP";. located at 29B Technology Drive, Irvine, CA
`92618, USA and Novartis Pharma AG ("Novartis") located at Forum 1, Novartis Campus, 4056
`Basel, Switzerland regarding an interest in evaluati11g certain of each other's business and
`technical information for the purpose of determining whether certain Novartis products are
`compatible with ASP's STERRAD® sterilization systems. In this regard, ASP wishes to
`evaluate certain information and data relating solely to Novartis' Lucentis® product (the
`"Product''), which Novartis considers to be confidential and proprietary. Novartis wishes to
`evaluate certain information and data relating to ASP's STERRAD® GMP sterilization systems
`(the "Systems"), which ASP considers to be confidential and proprietary. Each party agrees to
`disclose to and receive from the other, or allow the other to have access to, such party's
`confidential and proprietary information, only upon the following terms and conditions:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)01906307
`
`Novartis Exhibit 2147.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Novartis Pharma AG
`March 17, 2009
`Page2
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)01906307
`
`Novartis Exhibit 2147.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Novartis Pharma AG
`March 17, 2009
`Page3
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)01906307
`
`Novartis Exhibit 2147.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Novartis Pharma AG
`March 17. 2009
`Page4
`
`
`
`
`
`
`
`Very truly yours,
`
`Advanced Sterilization Product
`division of Ethicon, Inc.
`
`APPROVED AND ACCEPTED THIS __ DAY OF _________ , 2009.
`
`Novartis Pharma AG
`
`By:
`
`Title:
`
`By:
`
`Title:
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)01906307
`
`Novartis Exhibit 2147.004
`Regeneron v. Novartis, IPR2021-00816
`
`